Astragalus (TA-65) vs Fisetin
Two longevity supplements, two different mechanisms — lengthen the telomere, or clear the senescent cell. Both are sold well ahead of their evidence.
Astragalus (TA-65)
TA-65, a purified astragalus-root extract, has a real open-label human trial showing telomerase activation and improved biomarkers over a multi-year health-maintenance program — encouraging but industry-linked, uncontrolled, and a long way from a randomized longevity outcome.
Full Astragalus (TA-65) evidence reviewFisetin
The most potent senolytic flavonoid in mice, with lifespan data — but the one human trial to report a clinical outcome (ROPE, knee osteoarthritis) was null; other senolytic-hypothesis trials remain unpublished.
Full Fisetin evidence reviewSide by side
| Astragalus (TA-65) | Fisetin | |
|---|---|---|
| Marketed for | Telomerase activation, immune support, longevity | Senolytic, anti-aging |
| Evidence grade | Clinical data | Preclinical / minimal |
| Family | Senescence & senolytic | Senescence & senolytic |
| Key human source | TA-65 health maintenance program, Rejuvenation Res 2011 | Mouse senolytic, EBioMedicine 2018 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
TA-65, a purified astragalus-root extract, has a real open-label human trial reporting telomerase activation and improved biomarkers across a multi-year health-maintenance program — encouraging, but industry-linked, uncontrolled, and a long way from a randomized longevity outcome. Fisetin is the most potent senolytic flavonoid in mice and has mouse lifespan data behind it, yet the one human trial to report a clinical outcome, ROPE in knee osteoarthritis, was null, and other senolytic-hypothesis trials remain unpublished. Neither has a randomized human result supporting a longevity claim, and they have never been compared.
Astragalus (TA-65) fits if
You want the telomerase hypothesis and accept an uncontrolled, industry-linked human study as the best evidence available for it.
Fisetin fits if
You follow the senolytic hypothesis and accept that the mouse data is strong while the human read-outs so far are null or unpublished.